Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
2014 StandoutNobel
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
2002 Standout
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer
1999 Standout
Tumor Suppressor p53 Protein Is a New Target for the Metastasis-associated Mts1/S100A4 Protein
2001
Untangling the ErbB signalling network
2001 Standout
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
1997
Expression of uncoupling proteins-1, -2 and -3 mRNA is induced by an adenocarcinoma-derived lipid-mobilizing factor
2002
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.
1996
Interaction of Heparan Sulfate from Mammary Cells with Acidic Fibroblast Growth Factor (FGF) and Basic FGF
1998
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review
1995
Amplification of fgfr4 gene in human breast and gynecological cancers
1993
The Correlation Between Cytoplasmic Overexpression of Epidermal Growth Factor Receptor and Tumor Aggressiveness
2004
Inference and analysis of cell-cell communication using CellChat
2021 Standout
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
1999 Standout
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of HER-2/neu in Breast Cancer
1999
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers
2008
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
Binding to Intracellular Targets of the Metastasis-Inducing Protein, S100A4 (p9Ka)
2001
Estrogen Receptors and Distinct Patterns of Breast Cancer Relapse
2003
Breast cell invasive potential relates to the myoepithelial phenotype
2003
Shedding light onto live molecular targets
2003 Standout
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
2011 Standout
The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis
2002
Targeting hypoxia in cancer therapy
2011 Standout
Epithelial-mesenchymal transition and its implications for fibrosis
2003 Standout
Stromal fibroblasts in cancer initiation and progression
2004 StandoutNature
Estrogen receptors and human disease
2006 Standout
The hypoxic tumour microenvironment and metastatic progression
2003
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Hypoxia Regulates CD44 and Its Variant Isoforms through HIF-1α in Triple Negative Breast Cancer
2012 StandoutNobel
Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy
1994
Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy
1995
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer
2007
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
1992
Complex networks orchestrate epithelial–mesenchymal transitions
2006 Standout
The prognostic value of p53 and c-erb b-2 immunostaining is overrated for patients with lymph node negative breast carcinoma
2000
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
Exploiting tumour hypoxia in cancer treatment
2004 Standout
Trastuzumab‐associated cardiotoxicity
2002
Pathologies Involving the S100 Proteins and Rage
2007
Constitutive Protease-activated Receptor-2-mediated Migration of MDA MB-231 Breast Cancer Cells Requires Both β-Arrestin-1 and -2
2004 StandoutNobel
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
2001 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Calcium-binding protein S100A4 in health and disease
1998
Regulation of cancer cell metabolism
2011 Standout
FGF-21 as a novel metabolic regulator
2005 Standout
Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis
2009
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: Novel post-transcriptional, post-translational regulation
2005
Emerging Biological Principles of Metastasis
2017 Standout
Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy
2006
Comprehensive Proteomic Analysis of Breast Cancer Cell Membranes Reveals Unique Proteins with Potential Roles in Clinical Cancer
2003
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Tumour-educated macrophages promote tumour progression and metastasis
2004 Standout
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Novel Gliosarcoma Cell Line Expressing Green Fluorescent Protein: A Model for Quantitative Assessment of Angiogenesis
1998
Immunohistochemical Distinction of Invasive From Noninvasive Breast Lesions
2003
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Biomarkers for epithelial-mesenchymal transitions
2009 Standout
The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis
2014
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Osteopontin and the skin: multiple emerging roles in cutaneous biology and pathology
2009
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
2006 Standout
Molecular Regulation of Vascular Smooth Muscle Cell Differentiation in Development and Disease
2004 Standout
Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer
2008
Collective Invasion in Breast Cancer Requires a Conserved Basal Epithelial Program
2013
HIF and the Lung
2011 StandoutNobel
Tumor-Host Interactions: A Far-Reaching Relationship
2010
Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer.
1996
The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy
1998
An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Non–Small Cell Lung Cancers
2006
Clinical Usefulness of Estrogen Receptor Immunocytochemistry in Human Breast Cancer
1992
The extracellular matrix: A dynamic niche in cancer progression
2012 Standout
The Biology of Vascular Endothelial Growth Factor
1997 Standout
Plasticity of mammary epithelia during normal development and neoplastic progression
1998
The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis.
2003
Brown Adipose Tissue: Function and Physiological Significance
2004 Standout
2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*
2001
Fibroblast growth factors and their receptors
1997
Role of HER2 gene overexpression in breast carcinoma
2000
The Protein Kinase C Agonist PEP005 (Ingenol 3-Angelate) in the Treatment of Human Cancer: A Balance between Efficacy and Toxicity
2010
Human Macrophages Promote the Motility and Invasiveness of Osteopontin-Knockdown Tumor Cells
2007
Mechanisms of Diabetic Complications
2013 Standout
Estrogen Receptor Mutations in Human Disease
2004
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
2002 Standout
Epithelial-mesenchymal transition and its implications for fibrosis
2003 Standout
Euphorbia Diterpenes: Isolation, Structure, Biological Activity, and Synthesis (2008–2012)
2014 Standout
Functions of Cell Surface Heparan Sulfate Proteoglycans
1999 Standout
Metastatic Behavior of Breast Cancer Subtypes
2010 Standout
Osteopontin at the Crossroads of Inflammation and Tumor Progression
2017
Microvessel Density as a Prognostic Factor in Women with Breast Cancer
2004
Works of John Winstanley being referenced
The long term prognostic significance of c-erbB-2 in primary breast cancer
1991
Cytoplasmic staining of c-erbB-2 is not associated with the presence of detectable c-erbB-2 mRNA in breast cancer specimens
1998
Comparison of the metastasis-inducing protein S100A4 (p9ka) with other prognostic markers in human breast cancer
2000
Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease
1994
Variant estrogen receptor α mRNAs in human breast cancer specimens
2000
Immunocytochemical identification of cell types in benign and malignant breast diseases: variations in cell markers accompany the malignant state.
1993
Statistical Association of Basal Cell Keratins with Metastasis-Inducing Proteins in a Prognostically Unfavorable Group of Sporadic Breast Cancers
2011
Protein kinase C alpha expression in normal breast, ductal carcinoma in situ and invasive ductal carcinoma
2004
Examining the technique of angiogenesis assessment in invasive breast cancer
1997
Induction of Metastasis by S100P in a Rat Mammary Model and Its Association with Poor Survival of Breast Cancer Patients
2006
The expression of basic fibroblast growth factor and its receptor in cell lines derived from normal human mammary gland and a benign mammary lesion
1993
The long term prognostic significance of oestrogen receptor analysis in early carcinoma of the breast
1991
Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.
2002
Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer.
2006